Top 10 Oncology Capital Raises in the U.S. – January 1st-15th, 2025
Several interesting transactions closed in the Oncology sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
PIPE
-
- Bionano Genomics, a life sciences instrumentation company in the genome analysis space, received approximately $10 million of development capital through a private placement.
- Helix BioPharma, a clinical-stage biopharmaceutical company. It is focused on cancer drug development, received CAD 3 million of development capital through a private placement.
- Lipella Pharmaceuticals, a clinical-stage biotechnology company, received $875,500 of development capital through a private placement.
Merger/Acquisition and Corporate
-
- Poseida Therapeutics, a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need, was acquired by Roche for $1.5 billion.
- Tavros Therapeutics, developer of oncological drugs designed to treat cancer, was acquired by Vividion Therapeutics, a subsidiary of Bayer.
Later Stage VC
-
- Normunity, operator of a biotechnology company intended to create precision immuno-oncology medicines, raised $75 million of Series B venture funding in a deal led by Enavate Sciences and Samsara BioCapital.
- Umoja Biopharma, provider of immunotherapies intended to transform cancer treatment and improve quality of life, raised $100 million of Series C venture funding in a deal led by DCVC Bio and Double Point Ventures.
Early Stage VC
-
- Droplet Biosciences, operator of a molecular diagnostics company intended to improve cancer care through lymph liquid biopsy, raised $4.8 million of venture funding in the form of a convertible debt deal led by Safar Partners.
- Light Horse Therapeutics, operator of a small molecule drug discovery company intended to develop new CRISPR-based functional site-dependency maps, raised $62 million of Series A venture funding in a deal led by Versant Ventures.
Angel, Seed, and Grant
-
- Esphera SynBio, operator of a biotechnology company intended to develop cancer and immunoregulatory treatments through its innovative synthetic biology platform, raised $2 million of seed funding from GKCC and FACIT.
#castleplacement #capitalraising #privateequity #venturecapital #investment #oncology
Gary Levy
Managing Director
Over 30 years in financial services, including senior roles at Citi, Ivy Asset Management (an Affiliate of BNY) and TIAA. Founder and President of Biltmore Savings Consultants, a provider of B2B technology solutions to improve operations. Author of published book "21 Ways to Improve Your Business Operations." MBA - Strategic Business Management from Hofstra University’s Frank G. Zarb School of Business. BS (with a concentration in Business, Management and Economics) from SUNY Empire State College. Series 7, 63 and 79 licenses.
- Email: glevy@castleplacement.com
- (C) (516) 457-0104
 Gary LevyManaging Director |
Please contact me if you have any questions or would like to discuss your capital raise:
Email: glevy@castleplacement.com
(C) (516) 457-0104
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement™ does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.
